Clinical trials in process for cancerous disease of the pancreas, liver and/or bile ducts:
1) UAB 0560 and Affiliate - A Phase I Study Evaluating the Role of an Anti-Epidermal Growth Factor Receptor Antibody, C225, as a Radiosensitizer with Chemoradiation for Locally Advanced Pancreatic Cancer
Primary Sponsor: NIH/NCI
PI: Pablo Arnoletti (UAB)
Affiliate PIs: Selwyn Vickers, Ed Greeno (UMN)
Study Nurse: Carrie McCann
This is a new phase I, open label, non- randomized dose escalation study using Gemcitabine, and a new anti-epidermal growth factor receptor antibody (Cetuximab, C225), and radiation for the treatment of pancreatic cancer. Available to patients with locally unresectable disease.
Status: Open for enrollment
2) A Phase II Pilot Study of Multi-Agent Neo Adjuvant Chemoradiation in Patients with Locally Advanced Pancreatic Adenocarcinoma
PI: Ed Greeno (UMN)
Study Nurse: Carrie McCann
Status: Open for enrollment
3) CS1008-A-U201 - Phase 2, multicenter, open-label study of CS-1008, a humanized monoclonal antibody targeting death receptor 5 (DR5), in combination with gemcitabine in chemotherapy naïve subjects with unresectable or metastatic pancreatic cancer
Primary Sponsor: Daiichi Sankyo Pharma Development
Local PIs: Selwyn Vickers, Ed Greeno (UMN)
Study Nurse: Carrie McCann
This is a multicenter, phase II, open label study of CS-1008, a humanized, monomeric, bivalent, monoclonal IgG1 antibody, agonistic to the human death receptor 5 (DR5). The product was engineered from murine monoclonal antibody TRA-8. The proposed primary mechanism of anti-tumor activity of CS-1008 is induction of apoptosis through binding of DR5. Available to patients with locally unresectable disease or metastatic disease.
Status: Open for enrollment